At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 59 enrolled
Drug / intervention
Oral Magnesium Supplement +1 moredrug
Likely dose
400 mg Magnesium Citrate orally once daily for 12 weeksAI-extracted
Key inclusion· 3
- ✓Age 55 and older
- ✓Ability to speak English
- ✓Availability to attend baseline and follow-up visit approximately 12 weeks after baseline
Key exclusion· 5
- ✕Prior history of heart disease (coronary heart disease, heart failure, atrial fibrillation), stroke, or severe renal disease
- ✕Use of type I and III antiarrhythmics or digoxin
- ✕Current use of magnesium supplements
- ✕Any prior history of allergy or intolerance to magnesium
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias
In Brief
A Phase 2 clinical trial evaluating Oral Magnesium Supplement and Placebo for Premature Atrial Contraction. Completed, enrolled 59 participants across 1 site.
Detailed Summary
The primary objective of this research is to determine whether oral magnesium supplementation in healthy, community-living individuals will be associated with reductions in the burden of arrhythmias in the upper chambers of the heart (supraventricular arrhythmias).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPremature Atrial Contraction
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 2016
Enrollment StartMar 2017
Primary CompletionSep 2017
TodayJul 2026
First PostedJul 19, 2016
Enrollment StartMar 1, 2017
Primary CompletionSep 15, 2017
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 10.0 years ago
Interventions
Oral Magnesium Supplementdrug
400 mg Magnesium Citrate 1x daily for 12 weeks
Placebodrug
Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks